Published in BMC Genomics on March 27, 2009
Potential role for peptidylarginine deiminase 2 (PAD2) in citrullination of canine mammary epithelial cell histones. PLoS One (2010) 1.12
Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer (2010) 1.11
Breed-predispositions to cancer in pedigree dogs. ISRN Vet Sci (2013) 1.06
Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. BMC Cancer (2010) 1.03
Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation. PLoS One (2011) 0.97
Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates. BMC Cancer (2010) 0.97
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genomics (2013) 0.95
Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS One (2013) 0.95
Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. Mol Immunol (2012) 0.89
The gene expression profiles of canine mammary cancer cells grown with carcinoma-associated fibroblasts (CAFs) as a co-culture in vitro. BMC Vet Res (2012) 0.88
Similarity of markers identified from cancer gene expression studies: observations from GEO. Brief Bioinform (2013) 0.87
The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells. Oncol Lett (2013) 0.85
A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther (2010) 0.85
A role for T-lymphocytes in human breast cancer and in canine mammary tumors. Biomed Res Int (2014) 0.85
Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS One (2013) 0.84
Migrastatin analogues inhibit canine mammary cancer cell migration and invasion. PLoS One (2013) 0.81
Elucidation of how cancer cells avoid acidosis through comparative transcriptomic data analysis. PLoS One (2013) 0.81
Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. BMC Bioinformatics (2016) 0.81
Ligand-independent canonical Wnt activity in canine mammary tumor cell lines associated with aberrant LEF1 expression. PLoS One (2014) 0.81
In vitro comparative models for canine and human breast cancers. Clujul Med (2016) 0.80
Mammary stem cell research in veterinary science: an update. Stem Cells Dev (2013) 0.80
Effect of Melatonin in Epithelial Mesenchymal Transition Markers and Invasive Properties of Breast Cancer Stem Cells of Canine and Human Cell Lines. PLoS One (2016) 0.80
In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer (2015) 0.79
Pollutants in pet dogs: a model for environmental links to breast cancer. Springerplus (2015) 0.77
High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression. BMC Cancer (2015) 0.76
Hematoporphyrin monomethyl ether combined with He-Ne laser irradiation-induced apoptosis in canine breast cancer cells through the mitochondrial pathway. J Vet Sci (2016) 0.76
Diagnosing clean margins through Raman spectroscopy in human and animal mammary tumour surgery: a short review. Interface Focus (2016) 0.75
Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication? PLoS One (2014) 0.75
Relationship between major histocompatibility complex class I expression and prognosis in canine mammary gland tumors. J Vet Med Sci (2013) 0.75
Transcriptome and proteome research in veterinary science: what is possible and what questions can be asked? ScientificWorldJournal (2012) 0.75
Changes in mammary histology and transcriptome profiles by low-dose exposure to environmental phenols at critical windows of development. Environ Res (2016) 0.75
TD-GC-MS Investigation of the VOCs Released from Blood Plasma of Dogs with Cancer. Diagnostics (Basel) (2013) 0.75
Expression of endothelin-1 in laryngocarcinoma tissues and its clinical significance. Oncol Lett (2016) 0.75
Exploiting cancer genomics in pet animals to gain advantage for personalized medicine decisions. J Appl Genet (2014) 0.75
Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification. Front Vet Sci (2017) 0.75
Evaluation of expression of the Wnt signaling components in canine mammary tumors via RT(2) Profiler PCR Array and immunochemistry assays. J Vet Sci (2017) 0.75
Identification of prognostic collagen signatures and potential therapeutic stromal targets in canine mammary gland carcinoma. PLoS One (2017) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
[''R"--project for statistical computing]. Ugeskr Laeger (2008) 41.69
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res (2003) 29.26
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
PANTHER: a library of protein families and subfamilies indexed by function. Genome Res (2003) 21.64
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol (2001) 14.57
The druggable genome. Nat Rev Drug Discov (2002) 13.61
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
New developments in the InterPro database. Nucleic Acids Res (2007) 12.49
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
A module map showing conditional activity of expression modules in cancer. Nat Genet (2004) 8.57
Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8.37
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature (2006) 7.69
Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol (2006) 6.33
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A (2000) 6.30
Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A (2005) 6.26
Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer (2004) 6.07
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
Rosetta error model for gene expression analysis. Bioinformatics (2006) 4.67
oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res (2005) 4.52
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res (2005) 4.33
Modelling breast cancer: one size does not fit all. Nat Rev Cancer (2007) 3.64
CXC chemokines in angiogenesis. J Leukoc Biol (2000) 3.17
Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol (2002) 2.87
Functional and structural diversity of the human Dickkopf gene family. Gene (1999) 2.82
Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem (2007) 2.81
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res (2005) 2.65
The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol (2006) 2.58
Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res (2006) 2.46
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol (2008) 2.37
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer (2008) 2.13
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A (1995) 2.09
WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene (2002) 2.02
Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans--man and his best friend share more than companionship. Chromosome Res (2008) 1.87
Oncology of companion animals as a model for humans. an overview of tumor histotypes. J Exp Clin Cancer Res (2006) 1.72
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res (2008) 1.66
Profile of Ets gene expression in human breast carcinoma. Cancer Biol Ther (2007) 1.65
Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer (2004) 1.60
Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene (2004) 1.52
Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer (1997) 1.47
Regulation of mammary gland growth and morphogenesis by the mammary fat pad: a species comparison. J Mammary Gland Biol Neoplasia (1999) 1.36
Role of colony-stimulating factor-1 in reproduction and development. Mol Reprod Dev (1997) 1.36
Glutamine-dependent antiapoptotic interaction of human glutaminyl-tRNA synthetase with apoptosis signal-regulating kinase 1. J Biol Chem (2000) 1.34
Down-regulation of Wnt-4 and up-regulation of Wnt-5a expression by epithelial-mesenchymal transition in human squamous carcinoma cells. Cancer Sci (2003) 1.31
Revealing targeted therapy for human cancer by gene module maps. Cancer Res (2008) 1.29
MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem (2004) 1.27
Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis (2008) 1.27
Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother (2008) 1.23
Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett (2008) 1.21
Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br J Cancer (2003) 1.19
Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol (1999) 1.16
Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer (2005) 1.13
The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem (2004) 1.13
Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol (2005) 1.12
Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem (2004) 1.08
AMF1 (GPS2) modulates p53 transactivation. Mol Cell Biol (2001) 1.02
Estimating the neutral rate of nucleotide substitution using introns. Mol Biol Evol (2006) 1.00
Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer (2002) 0.99
Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today (1997) 0.99
Mammary gland macrophages: pleiotropic functions in mammary development. J Mammary Gland Biol Neoplasia (2006) 0.97
Loss of net as repressor leads to constitutive increased c-fos transcription in cervical cancer cells. J Biol Chem (2004) 0.94
Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie (2004) 0.91
Capsaicin-induced inactivation of sensory neurons promotes a more aggressive gene expression phenotype in breast cancer cells. Breast Cancer Res Treat (2006) 0.91
Aberrations of the p53 tumor suppressor gene in various tumors in dogs. Am J Vet Res (2001) 0.90
Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci (1999) 0.90
Overexpression of the p53 gene product in canine mammary tumors. Oncol Rep (2001) 0.83
Transcriptional coordination of the genes encoding catalytic (CK2alpha) and regulatory (CK2beta) subunits of human protein kinase CK2. Mol Cell Biochem (2001) 0.83
Latent transforming growth factor binding protein 4 (LTBP-4) is downregulated in human mammary adenocarcinomas in vitro and in vivo. APMIS (2007) 0.83
UICC Study Group on chemosensitivity testing of human tumors. Problems--applications--future prospects. Int J Cancer (1986) 0.83
ERK/MAPK regulation of the androgen responsiveness of breast cancer cells. Adv Exp Med Biol (2008) 0.81
Development of a stabilized form of the regulatory CK2beta subunit that inhibits cell proliferation. J Biol Chem (2007) 0.80
Mast cell tumors of the gastrointestinal tract in 39 dogs. Vet Pathol (2002) 0.79
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science (2003) 16.80
An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet (2005) 11.40
Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet (2005) 8.23
Defining the regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2. Genes Dev (2008) 4.24
A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med (2006) 3.12
Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide synthesis. Nat Methods (2004) 3.01
Ottawa Hospital Patient Safety Study: incidence and timing of adverse events in patients admitted to a Canadian teaching hospital. CMAJ (2004) 2.45
The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med (2009) 2.38
A comprehensive transcript index of the human genome generated using microarrays and computational approaches. Genome Biol (2004) 2.21
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet (2012) 2.09
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 2.08
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol (2003) 2.03
Analysis of prognostic factors associated with injection-site sarcomas in cats: 57 cases (2001-2007). J Am Vet Med Assoc (2008) 1.99
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology (2004) 1.91
Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol (2003) 1.89
Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System. BMC Res Notes (2009) 1.80
Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer (2008) 1.78
Individual-specific variation of gene expression in peripheral blood leukocytes. Genomics (2004) 1.75
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
RNA-Seq Atlas--a reference database for gene expression profiling in normal tissue by next-generation sequencing. Bioinformatics (2012) 1.74
Expression of alternatively spliced sodium channel alpha-subunit genes. Unique splicing patterns are observed in dorsal root ganglia. J Biol Chem (2004) 1.67
Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology (2003) 1.66
Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med (2003) 1.66
Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A (2012) 1.65
Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes. J Hepatol (2007) 1.54
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics (2010) 1.50
Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. Hum Gene Ther (2002) 1.50
Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine. Vaccine (2012) 1.49
Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: initial identification of predictive biomarkers. Eur J Immunol (2006) 1.49
Pemphigus foliaceus in a goat. Vet Dermatol (2002) 1.47
Evolution of bacterial and archaeal multicomponent monooxygenases. J Mol Evol (2003) 1.46
Galaxy LIMS for next-generation sequencing. Bioinformatics (2013) 1.45
Percutaneous transluminal renal stenting for transplant renal artery stenosis. Catheter Cardiovasc Interv (2011) 1.41
Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). J Med Internet Res (2011) 1.39
Feline perforating dermatitis resembling human reactive perforating collagenosis: clinicopathological findings and outcome in four cases. Vet Dermatol (2009) 1.39
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett (2008) 1.37
Carbon Dioxide versus Saline Tissue Expanders: Does It Matter? Plast Reconstr Surg (2016) 1.36
Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol (2011) 1.36
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res (2008) 1.33
Quality of life in patients with psoriasis. Health Qual Life Outcomes (2006) 1.31
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood (2006) 1.28
Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle (2010) 1.28
Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS One (2011) 1.26
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res (2008) 1.26
The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget (2012) 1.25
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry (2004) 1.21
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res (2010) 1.19
IL-6 is required for airway mucus production induced by inhaled fungal allergens. J Immunol (2009) 1.17
Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling. J Biol Chem (2006) 1.15
Spheres derived from lung adenocarcinoma pleural effusions: molecular characterization and tumor engraftment. PLoS One (2011) 1.14
Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene (2011) 1.14
Growth delay of human bladder cancer cells by Prostate Stem Cell Antigen downregulation is associated with activation of immune signaling pathways. BMC Cancer (2010) 1.11
Validation studies of the site-directed docking program LibDock. J Chem Inf Model (2007) 1.11
Redescription of Onchocerca lupi (Spirurida: Onchocercidae) with histopathological observations. Parasit Vectors (2013) 1.08
Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol (2005) 1.07
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J Transl Med (2013) 1.05
Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol (2006) 1.05
Feline leishmaniosis due to Leishmania infantum in Italy. Vet Parasitol (2002) 1.03
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. Oncotarget (2013) 1.03
The negative impact of psoriasis on the workplace. J Dermatolog Treat (2006) 1.03
Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer (2005) 1.02
Cross-hybridization on PCR-spotted microarrays. IEEE Eng Med Biol Mag (2002) 1.01
Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol (2004) 1.00
Proliferative and necrotising otitis externa in a cat without pinnal involvement: video-otoscopic features. J Feline Med Surg (2012) 1.00
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res (2008) 0.99
Regional collaborations as a tool for quality improvements in surgery: a systematic review of the literature. Ann Surg (2009) 0.99
Infection of U937 monocytic cells with Chlamydia pneumoniae induces extensive changes in host cell gene expression. J Infect Dis (2003) 0.99
Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Cancer Res (2002) 0.98
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J Transl Med (2013) 0.98
Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. J Cell Physiol (2012) 0.98